{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:05:34Z","timestamp":1792242334000,"version":"4.4.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jad.2024.07.034","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T17:35:38Z","timestamp":1721064938000},"page":"552-559","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Clinical safety of daridorexant in insomnia treatment: Analysis of FDA adverse event reports"],"prefix":"10.1016","volume":"362","author":[{"given":"Qi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haohao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2024.07.034_bb0005","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation[J]","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.jad.2024.07.034_bb0010","doi-asserted-by":"crossref","first-page":"zsaa275","DOI":"10.1093\/sleep\/zsaa275","article-title":"Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea[J]","volume":"44","author":"Boof","year":"2021","journal-title":"Sleep"},{"issue":"23","key":"10.1016\/j.jad.2024.07.034_bb0015","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/cmdc.202000453","article-title":"The quest for the best dual orexin receptor antagonist (daridorexant) for the treatment of insomnia disorders[J]","volume":"15","author":"Boss","year":"2020","journal-title":"ChemMedChem"},{"issue":"8","key":"10.1016\/j.jad.2024.07.034_bb0020","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management[J]","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf."},{"key":"10.1016\/j.jad.2024.07.034_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.smrv.2021.101492","article-title":"Effects of hypnotics on obstructive sleep apnea endotypes and severity: novel insights into pathophysiology and treatment[J]","volume":"58","author":"Carter","year":"2021","journal-title":"Sleep Med. Rev."},{"key":"10.1016\/j.jad.2024.07.034_bb0030","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3389\/fphys.2017.00357","article-title":"Orexin system: the key for a healthy life[J]","volume":"8","author":"Chieffi","year":"2017","journal-title":"Front. Physiol."},{"issue":"1","key":"10.1016\/j.jad.2024.07.034_bb0035","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/jcm11010067","article-title":"Sleep problems in chronic inflammatory diseases: prevalence, treatment, and new perspectives: a narrative review[J]","volume":"11","author":"Ditmer","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jad.2024.07.034_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112141","article-title":"Soporific effect of modified Suanzaoren Decoction on mice models of insomnia by regulating Orexin-A and HPA axis homeostasis[J]","volume":"143","author":"Dong","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.jad.2024.07.034_bb0045","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system[J]","volume":"53","author":"DuMouchel","year":"1999","journal-title":"Am. Stat."},{"issue":"6","key":"10.1016\/j.jad.2024.07.034_bb0050","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports[J]","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"Supplement_2","key":"10.1016\/j.jad.2024.07.034_bb0055","doi-asserted-by":"crossref","first-page":"A25","DOI":"10.1093\/sleep\/zsab072.058","article-title":"059 Daridorexant: a dual, equipotent, and insurmountable antagonist of both orexin-1 and orexin-2 receptors[J]","volume":"44","author":"Grandjean","year":"2021","journal-title":"Sleep"},{"key":"10.1016\/j.jad.2024.07.034_bb0060","first-page":"1","article-title":"The correlation of Esketamine with specific adverse events: a deep dive into the FAERS database[J]","author":"Jiang","year":"2023","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jad.2024.07.034_bb0065","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","article-title":"Safety assessment of Brexpiprazole: real-world adverse event analysis from the FAERS database[J]","volume":"346","author":"Jiang","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"2","key":"10.1016\/j.jad.2024.07.034_bb0070","doi-asserted-by":"crossref","first-page":"zsaa169","DOI":"10.1093\/sleep\/zsaa169","article-title":"Gender differences in nighttime sleep patterns and variability across the adult lifespan: a global-scale wearables study[J]","volume":"44","author":"Jonasdottir","year":"2021","journal-title":"Sleep"},{"key":"10.1016\/j.jad.2024.07.034_bb0075","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.jad.2022.12.005","article-title":"The real-world burden of adults with major depressive disorder with moderate or severe insomnia symptoms in the United States[J]","volume":"323","author":"Joshi","year":"2023","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.jad.2024.07.034_bb0080","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40263-022-00980-8","article-title":"Long-term safety and tolerability of daridorexant in patients with insomnia disorder[J]","volume":"37","author":"Kunz","year":"2023","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.jad.2024.07.034_bb0085","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40265-022-01699-y","article-title":"Daridorexant: first approval[J]","volume":"82","author":"Markham","year":"2022","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.jad.2024.07.034_bb0090","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1474-4422(21)00436-1","article-title":"Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials[J]","volume":"21","author":"Mignot","year":"2022","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.jad.2024.07.034_bb0095","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1474-4422(21)00436-1","article-title":"Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials[J]","volume":"21","author":"Mignot","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jad.2024.07.034_bb0100","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2147\/NSS.S201994","article-title":"Targeting orexin receptors for the treatment of insomnia: from physiological mechanisms to current clinical evidence and recommendations[J]","author":"Mogavero","year":"2023","journal-title":"Nat. Sci. Sleep"},{"issue":"2","key":"10.1016\/j.jad.2024.07.034_bb0105","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jsmc.2022.03.003","article-title":"Epidemiology of insomnia: prevalence, course, risk factors, and public health burden[J]","volume":"17","author":"Morin","year":"2022","journal-title":"Sleep Med. Clin."},{"issue":"4","key":"10.1016\/j.jad.2024.07.034_bb0110","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1097\/MJT.0000000000001647","article-title":"Daridorexant, an orexin receptor antagonist for the management of insomnia[J]","volume":"30","author":"Najib","year":"2023","journal-title":"Am. J. Ther."},{"issue":"4","key":"10.1016\/j.jad.2024.07.034_bb0115","doi-asserted-by":"crossref","first-page":"47791","DOI":"10.4088\/JCP.23lr14892a","article-title":"Daridorexant: caution is needed about suicidal risk in depressed patients with insomnia\u2014reply to Palagini et al[J]","volume":"84","author":"Nobile","year":"2023","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2024.07.034_bb0120","doi-asserted-by":"crossref","first-page":"44433","DOI":"10.4088\/JCP.22l14628","article-title":"Possible suicidal risk with daridorexant, a new treatment for insomnia[J]","volume":"84","author":"Nobile","year":"2022","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2024.07.034_bb0125","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3667","article-title":"The effects of sleep disruption on metabolism, hunger, and satiety, and the influence of psychosocial stress and exercise: a narrative review[J]","volume":"40","author":"Rogers","year":"2024","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.jad.2024.07.034_bb0130","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.2147\/NDT.S297504","article-title":"Advances in the treatment of chronic insomnia: a narrative review of new nonpharmacologic and pharmacologic therapies[J]","author":"Rosenberg","year":"2021","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"8","key":"10.1016\/j.jad.2024.07.034_bb0135","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio[J]","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"8","key":"10.1016\/j.jad.2024.07.034_bb0140","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40261-021-01062-1","article-title":"Impact of daridorexant, a dual orexin receptor antagonist, on cardiac repolarization following bedtime dosing: results from a thorough QT study using concentration-QT analysis[J]","volume":"41","author":"Schilling","year":"2021","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.jad.2024.07.034_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.smrv.2021.101573","article-title":"The efficacy and safety of dual orexin receptor antagonists in primary insomnia: a systematic review and network meta-analysis[J]","volume":"61","author":"Xue","year":"2022","journal-title":"Sleep Med. Rev."},{"issue":"21","key":"10.1016\/j.jad.2024.07.034_bb0150","doi-asserted-by":"crossref","first-page":"e2222","DOI":"10.1212\/WNL.0000000000009475","article-title":"Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder[J]","volume":"94","author":"Zammit","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.jad.2024.07.034_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.sleepe.2023.100068","article-title":"The effects of different dosages of dual orexin receptor antagonists and zolpidem on sleep and cognitive function: a meta-analysis and systematic review[J]","volume":"3","author":"Zhou","year":"2023","journal-title":"Sleep Epidemiol."},{"key":"10.1016\/j.jad.2024.07.034_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2023.103828","article-title":"Adverse events of epidiolex: a real-world drug safety surveillance study based on the FDA adverse event reporting system (FAERS) database[J]","volume":"90","author":"Zhou","year":"2023","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.jad.2024.07.034_bb0165","doi-asserted-by":"crossref","first-page":"1029554","DOI":"10.3389\/fnhum.2022.1029554","article-title":"Orexin dual receptor antagonists, zolpidem, zopiclone, eszopiclone, and cognitive research: a comprehensive dose-response meta-analysis[J]","volume":"16","author":"Zhou","year":"2023","journal-title":"Front. Hum. Neurosci."},{"key":"10.1016\/j.jad.2024.07.034_bb0170","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jad.2023.11.076","article-title":"Mining and analysis of adverse event signals of Cariprazine based on the real-world data of FAERS database[J]","volume":"347","author":"Zhu","year":"2024","journal-title":"J. Affect. Disord."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724010905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724010905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T16:53:26Z","timestamp":1742230406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032724010905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":34,"alternative-id":["S0165032724010905"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2024.07.034","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical safety of daridorexant in insomnia treatment: Analysis of FDA adverse event reports","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2024.07.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}